The National Science Foundation awarded Theracea Pharma LC a $256,000 Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop bioconjugation and preparation of fluorine-18 biomolecules for positron emission tomography (PET) imaging. The grant period runs from August 15, 2021 through July 31, 2023 in Tucson, Arizona. Under this award, Theracea Pharma LC will work to advance science and engineering research and innovation leading to breakthrough technologies as well as solutions to national challenges through developing methods for labeling biomolecules with radioactive fluorine-18 for use in PET imaging procedures. The funding will support Theracea Pharma LC's work in bioconjugation chemistry and production of PET radiotracers over the two year grant period.
Generated 1/7/24, 7:03 AM